The thesis

Black Diamond Therapeutics operates in biotechnology, focusing on genetically characterized tumors with its pipeline lead BDTX-189. The company's conviction score is 6/100, indicating a dormant status. Despite a buy consensus from analysts, its P/E ratio is -2.5x, suggesting significant investor skepticism. The current macro context of tightening monetary policy may impact consumer discretionary spending, but biotech remains a defensive sector.

Why now

A potential risk-on rotation in biotech, driven by advancements in pipeline assets like BDTX-189, could revalue Black Diamond Therapeutics. The company's dormant conviction status (6/100) suggests it is underfollowed, making it ripe for revaluation.

What to watch

Progress on BDTX-189's clinical trials and any regulatory updates over the next quarter will be key indicators of the company's potential. A shift in the conviction score, indicating increased analyst attention, would also confirm the thesis.

Key risks

Execution risk around BDTX-189's clinical trials and regulatory approvals is high. A sustained tightening of monetary policy could negatively impact investor appetite for riskier biotech stocks.

Theme exposure